BPC-157 (10mg) is examined for angiogenesis and tendon-to-bone pathways, TB-500 (10mg) for cell migration and actin remodeling, and GHK-Cu (50mg) for collagen organization and copper-dependent antioxidant activity
Running GHK-Cu during active fat loss, rather than after, puts these regenerative signals in place while the extracellular matrix is most responsive to remodeling stimulus
PMID: 32308787
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
To make this even clearer, here's a simple comparison table our lab team put together
Clinical Context: The Phase 2 trial by Metabolic Pharmaceuticals found significant fat loss at 1mg (1,000mcg)/day over 12 weeks compared to placebo